Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
There is considerable evidence that lack of p16 protein expression is a frequent event in human gliomas. Nevertheless, the molecular mechanisms underlying this absence of p16 protein expression are not completely understood. In some gliomas, homozygous deletions are the main cause of p16/CDKN2 gene inactivation. However, other gliomas lacking p16 expression exhibit intact p16/CDKN2 gene, suggesting that p16/CDKN2 is down-regulated at the transcriptional level. In this study we investigated whether aberrant p16/CDKN2 gene methylation correlated with absence of p16 expression in the latter group of gliomas. In a series of 27 gliomas, 12 malignant tumors exhibited loss of p16/CDKN2 expression but not gene deletion. Methylation analysis of the CpG island in the 5' region of the p16/CDKN2 gene showed that exon 1 was extensively methylated in six and partially methylated in the other six of the 12 malignant gliomas. In contrast, no methylation was observed in four other malignant gliomas and two low-grade gliomas that expressed p16 protein. These results indicate that abnormal hypermethylation of the CpG island encompassing the 5' end of the p16/CDKN2 gene may be a mechanism of transcriptional silencing in gliomas without homozygous deletions.
Fueyo
J
J
Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.
Gomez-Manzano
C
C
Bruner
J M
JM
Saito
Y
Y
Zhang
B
B
Zhang
W
W
Levin
V A
VA
Yung
W K
WK
Kyritsis
A P
AP
D001932:Brain Neoplasms / Q000235:genetics*; D002352:Carrier Proteins / Q000235:genetics / Q000378:metabolism*; D019941:Cyclin-Dependent Kinase Inhibitor p16; D015226:Dinucleoside Phosphates / Q000378:metabolism*; D015536:Down-Regulation; D005910:Glioma / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry; D008745:Methylation
D002352:Carrier Proteins; D019941:Cyclin-Dependent Kinase Inhibitor p16; D015226:Dinucleoside Phosphates; C015772:CpG dinucleotide